GO
Loading...

Merck & Co Inc

More

  • Glaxo's Avandia Raises Heart Disease Risk: Study Monday, 21 May 2007 | 5:29 PM ET

    GlaxoSmithKline's widely prescribed diabetes drug Avandia is linked to a greater risk of heart attack and possibly death, a new scientific analysis revealed, and the U.S. government issued a safety alert.

  • Siemens Taps Merck Executive As New CEO Sunday, 20 May 2007 | 1:07 PM ET

    The supervisory board of German engineering conglomerate Siemens announced Sunday it has tapped Peter Loescher as its new CEO as the company struggles to improve an image tarnished by corruption.

  • Company-Changing CEOs Monday, 14 May 2007 | 8:19 PM ET

    This week Cramer is doing a series on CEOs, the best of the best when it comes to company turnarounds. These five executives have turned their once-dead franchises into living, thriving businesses. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • German drug maker Merck announced that it is selling its generic drug business to Mylan Laboratories  for $6.6 billion.

  • Stocks That Pay Dividends Are A Good Bet For Retirement Thursday, 10 May 2007 | 10:26 AM ET

    Joseph Keating, chief investment officer at First American Asset Management, told CNBC’s “Squawk on the Street” that dividend stocks are a good bet in retirement.

  • Medical Journal Raises Questions About Merck Vaccine Wednesday, 9 May 2007 | 6:07 PM ET

    The New England Journal of Medicine said in an editorial Wednesday that Merck's Gardasil, a treatment for human papillomavirus or HPV, appears to be safe and effective but "a cautious approach may be warranted" due to unanswered questions about the drug's long-term effectiveness and potential for adverse effects that could emerge over time.

  • Pharmaceuticals a Good Bet, Analysts Say Tuesday, 8 May 2007 | 1:10 PM ET

    Michael Krensavage, pharmaceutical analyst at Raymond James, told CNBC’s “Morning Call” that strong revenue and earnings growth will reward investors in the pharmaceutical sector.

  • It's Time for the Lightning Round! Friday, 4 May 2007 | 6:55 PM ET

    Sears, Bank of New York, Amgen and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Generics Unit of Germany's Merck Gets Four Final Bids Tuesday, 1 May 2007 | 12:55 AM ET

    Merck, Germany's drugs and chemicals group, received four final bids for its generics drugs business, sources familiar with the situation said on Monday.

  • Merck's Vioxx Successor Rejected by FDA Friday, 27 Apr 2007 | 4:12 PM ET

    The decision was widely expected, after a panel of FDA advisers two weeks ago voted 20-1 against approving the drug, Arcoxia.

  • Several other major drug companies were apparently interested in buying MedImmune, including Merck, Eli Lilly and possibly Novartis, CNBC’s David Faber reported Tuesday.

  • Demand for a free vaccine against cervical cancer is outstripping supply in New Hampshire, which was the first state in the country to approve free distribution of the vaccine, which protects girls against four strains of a sexually transmitted infection called human papillomavirus, or HPV.

  • A Texas judge overseeing lawsuits against Merck over its withdrawn pain drug Vioxx dismissed a case, rejecting the plaintiff's claim that she was not properly informed of the health risks associated with the medicine, Merck said late on Friday.

  • Pfizer said quarterly earnings fell 18%, hurt by one-time charges and anemic sales of inhaled diabetes drug Exubera, plunging demand for drugs facing generic competition. The world's largest drugmaker also warned its 2007 earnings will be below Wall Street expectations due to the unexpectedly swift introduction of cheaper generic forms of its hypertension treatment Norvasc.

  • Stocks Close Mixed But Dow Edges Up to Another Record Thursday, 19 Apr 2007 | 5:10 PM ET

    Stocks closed mixed but the Dow Jones Industrial Average inched up to another record as investors awaited key quarterly reports after the bell.  "You still have some pretty important earnings coming out that are going to set the tone," said Adam Tracy, director of listed trading at Thomas Weisel Partners.

  • Schering-Plough Beats Earnings Forecasts By Wide Margin Thursday, 19 Apr 2007 | 11:00 AM ET

    Schering-Plough reported strong first-quarter results, surpassing consensus estimates by a wide margin due to robust sales of cholesterol drugs and allergy treatments.

  • Merck Profit Beats Estimates As Sales of New Drugs Jump Thursday, 19 Apr 2007 | 9:00 AM ET

    Merck  said quarterly earnings rose as booming sales of newer medicines offset declines in older products, and said it plans to seek U.S. approval in 2009 for a migraine-headache treatment now entering late-stage trials.

  • CNBC's Domm: Today's Agenda in the Markets Thursday, 19 Apr 2007 | 8:59 AM ET

    China's rapid growth is a double-edged sword and today it is cutting into world equities markets. Asian and European markets were lower and U.S. stocks are pointing at a weaker opening, with the Dow, fresh off a new high, looking particularly wobbly. Earnings news is also setting the tone.

  • MedImmune may be close to completing a sale of the company just days after the drugmaker said it hired Goldman Sachs to explore opportunities, sources told CNBC's David Faber on Wednesday. "They are looking to get this deal done over the weekend," Faber said. "Monday morning is what I'm hearing."

  • Glaxo, Merck Maneuver for Position in HPV Drug Market Tuesday, 17 Apr 2007 | 3:41 PM ET

    Merck and GlaxoSmithKline both released news about their respective treatments for human papillomavirus Tuesday, leaving them "duking it out over what's expected to be the multi-billion dollar HPV cervical cancer vaccine market," reported CNBC's Mike Huckman.

Most Popular Video

Thursday, 17 Apr 2014 | 4:13 PM ET

Dissecting today's market activity and the current state of financials, with Yra Harris, Praxis Trading partner; Larry Glazer, Mayflower Advisors; CNBC contributor Carol Roth; "Fast Money" Guy Adami and CNBC's Kate Kelly.

Thursday, 17 Apr 2014 | 5:46 PM ET

CNBC voice over talent Jim Birdsall shares the top 5 sayings from traders on "Fast Money" over the years.

Thursday, 17 Apr 2014 | 6:40 PM ET

Mad Money's Jim Cramer reflects on CNBC's evolution over the past 25 years.